Company Overview of Algeta ASA
Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA wa...
Kjelsåsveien 172 A
PO Box 54 Kjelsås
Founded in 1997
47 23 00 79 90
47 23 00 79 91
Key Executives for Algeta ASA
Co-Founder and Member of Scientific Advisory Board
Senior Vice President of Quality and Regulatory Affairs
Senior Vice President and Executive Advisor
Compensation as of Fiscal Year 2015.
Algeta ASA Key Developments
Algeta ASA Announces Management Changes
Mar 14 14
Algeta ASA announced that Dr. Ramdahl succeeds company's former CEO Andrew Kay. Thomas Ramdahl has been with Algeta in various leadership roles since 2001, including serving as the CEO until 2009. Thomas Ramdahl reports to Oliver Rittgen, the CEO of Bayer Nordic and the Chairman of the board at the company.
Algeta ASA, Special/Extraordinary Shareholders Meeting, Mar 14, 2014
Mar 13 14
Algeta ASA, Special/Extraordinary Shareholders Meeting, Mar 14, 2014., at 10:00 Central European Standard Time. Location: Arne Jacobsens Allé 13. Agenda: To consider election of a chairperson and a person to co-sign the minutes; to seek approval of the notice and the agenda; to seek changes to the articles of association; to seek election of a new board of directors; to seek application for de-listing of the shares in Algeta ASA from Oslo Stock Exchange.
Algeta ASA(OB:ALGETA) dropped from Oslo OBX Total Return Index
Feb 24 14
Algeta ASA will be removed from the Oslo OBX Total Return Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries